Modality
mRNA
MOA
KRASG12Ci
Target
CD19
Pathway
Tau
EpilepsyOvarian Ca
Development Pipeline
Preclinical
~Feb 2021
→ ~May 2022
Phase 1
Aug 2022
Phase 1Current
NCT06044735
872 pts·Ovarian Ca
2022-08→TBD·Not yet recruiting
872 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06044735 | Phase 1/2 | Ovarian Ca | Not yet recr... | 872 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |